Scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method — as well as a trio of successful animal studies on an antibody called ‘Ab1’ — are described today in a new study. Ab1 is on track for human clinical trials by early next year.
